Loading...
•
Sep 30, 2024
ADMA Biologics Q3 2024 Earnings Report
ADMA Biologics demonstrated strong financial performance in Q3 2024, marked by significant revenue growth and increased profitability.
Key Takeaways
ADMA Biologics reported a substantial increase in revenue and net income for Q3 2024. Total revenue grew by 78% year-over-year to $119.8 million, while GAAP net income increased by 1,300% to $35.9 million. The company also raised its full-year revenue, net income, and adjusted EBITDA guidance for 2024 and 2025.
Total revenue increased by 78% year-over-year, reaching $119.8 million.
GAAP net income grew by 1,300% year-over-year, amounting to $35.9 million.
Adjusted EBITDA increased by 256% year-over-year, totaling $45.4 million.
Full-year revenue and earnings guidance for 2024 and 2025 was raised.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA Biologics raised its financial guidance for fiscal years 2024 and 2025, expecting revenue to exceed $415 million and $465 million, respectively, and GAAP net income to exceed $120 million and $165 million, respectively. Adjusted EBITDA is projected to exceed $160 million and $215 million for the same periods.
Positive Outlook
- Total revenue is now expected to be more than $415 million for FY 2024.
- Total revenue is now expected to be more than $465 million for FY 2025.
- GAAP net income is now expected to exceed $120 million for FY 2024.
- GAAP net income is now expected to exceed $165 million for FY 2025.
- Adjusted EBITDA is now expected to exceed $160 million for FY 2024.